This collaboration builds on BPGbio’s first-in-class E2-based protein degradation program, which features a proprietary library of more than 1,000 Ro3 fragments discovered by BPGbio that are potential ligands and seed compounds to a variety of E2 targets, proprietary ternary structures, a computational tool kit for E2 ligand design, and assays for rapidly attaining selectivity and specificity.
The partnership will leverage the Centre for Medicines Discovery’s expertise in translational research, including their groundbreaking efforts in neurological diseases such as Parkinson’s. The team will utilize BPGbio’s proprietary NAi Interrogative Biology® Platform, which integrates patient biology with AI-driven analysis, to accelerate biomarker discovery and therapeutics development.
The initial phase of the collaboration will focus on the validation of BPGbio’s E2 based Targeted Protein Degradation technology. The collaboration will expand the field by identifying novel degradable targets and will generate high quality publications.
Professor Paul Brennan, Director of the Centre for Medicines Discovery, said: ‘Partnering with BPGbio, we’re combining our world-class translational research expertise with their pioneering approach to protein degradation. This collaboration has the potential to unlock new therapeutic strategies for diseases that have long resisted treatment, including challenging cancers and central nervous system disorders. We are excited to explore novel targets and bring forward breakthrough therapies that could make a profound difference for patients.’
Dr Niven R. Narain, President and CEO of BPGbio, said: ‘This collaboration represents a powerful alliance of biology-first science and cutting-edge translational research. By harnessing our NAi Interrogative Biology Platform alongside Oxford’s expertise, we aim to push the boundaries of protein degradation science and deliver transformative therapies for diseases like cancer and central nervous system disorders, where unmet medical needs remain significant.’